We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Spectrum's (SPPI) NDA for NSCLC Candidate Gets CRL From FDA
Read MoreHide Full Article
Spectrum Pharmaceuticals, Inc. announced that the company has received a Complete Response Letter (CRL) from the FDA regarding its new drug application (NDA) for pipeline candidate, poziotinib.
Shares were down on the news but the decline was later on pared with shares gaining 7.6% and the company finally ended trading in green on Nov 25.
The company sought approval of the candidate for the treatment of patients with previously treated locally advanced or metastatic non-small cell lung cancer ("NSCLC") harboring HER2 exon 20 insertion mutations.
The FDA issued a CRL indicating the poziotinib application cannot be approved in its present form and the agency requires additional data, including a randomized controlled study, prior to approval.
The CRL did not come as a surprise to the company, as the Oncologic Drugs Advisory Committee of the FDA had earlier voted 9-4 that the current benefits of poziotinib did not outweigh its risks.
Consequently, the company will de-prioritize poziotinib program activities and reduce its workforce by 75%. Per the company, the anticipated cost savings from this restructuring should enable the company to generate the working capital required to support its strategic refocusing through 2024.
Poziotinib is a novel, oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that inhibits the tyrosine kinase activity of EGFR as well as HER2 and HER4, which, in turn, leads to the inhibition of the proliferation of tumor cells that overexpress these receptors.
The company has an exclusive license from the South Korean company Hanmi Pharmaceutical to develop and commercialize poziotinib all over the world, excluding Korea and China.
Shares of Spectrum have plunged 61.5% in the year-to-date period compared with the industry’s decline of 30.3%.
Image Source: Zacks Investment Research
Spectrum will now focus its efforts on driving growth from its recently launched commercial drug, Rolvedon. The drug was approved in September 2022 for adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
As of Sep 30, 2022, Spectrum had $100.3 million of cash, cash equivalents, and marketable securities.
Over the past 30 days, earnings estimates for Biogen have increased by 30 cents to $16.98. Biogen also surpassed estimates in three of the trailing four quarters, with the average being 7.02%.
Over the past 30 days, earnings estimates for Gilead have increased by 55 cents to $7.09. Gilead also surpassed estimates in three of the trailing four quarters, with the average being 0.35%.
Over the past 30 days, loss estimates for Solid Biosciences have narrowed to $8.04 from $10.15. SLDB missed estimates in three of the trailing four quarters, with the average being -4.15%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Spectrum's (SPPI) NDA for NSCLC Candidate Gets CRL From FDA
Spectrum Pharmaceuticals, Inc. announced that the company has received a Complete Response Letter (CRL) from the FDA regarding its new drug application (NDA) for pipeline candidate, poziotinib.
Shares were down on the news but the decline was later on pared with shares gaining 7.6% and the company finally ended trading in green on Nov 25.
The company sought approval of the candidate for the treatment of patients with previously treated locally advanced or metastatic non-small cell lung cancer ("NSCLC") harboring HER2 exon 20 insertion mutations.
The FDA issued a CRL indicating the poziotinib application cannot be approved in its present form and the agency requires additional data, including a randomized controlled study, prior to approval.
The CRL did not come as a surprise to the company, as the Oncologic Drugs Advisory Committee of the FDA had earlier voted 9-4 that the current benefits of poziotinib did not outweigh its risks.
Consequently, the company will de-prioritize poziotinib program activities and reduce its workforce by 75%. Per the company, the anticipated cost savings from this restructuring should enable the company to generate the working capital required to support its strategic refocusing through 2024.
Poziotinib is a novel, oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that inhibits the tyrosine kinase activity of EGFR as well as HER2 and HER4, which, in turn, leads to the inhibition of the proliferation of tumor cells that overexpress these receptors.
The company has an exclusive license from the South Korean company Hanmi Pharmaceutical to develop and commercialize poziotinib all over the world, excluding Korea and China.
Shares of Spectrum have plunged 61.5% in the year-to-date period compared with the industry’s decline of 30.3%.
Image Source: Zacks Investment Research
Spectrum will now focus its efforts on driving growth from its recently launched commercial drug, Rolvedon. The drug was approved in September 2022 for adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
As of Sep 30, 2022, Spectrum had $100.3 million of cash, cash equivalents, and marketable securities.
Zacks Rank & Stocks to Consider
Spectrum currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the healthcare sector include Biogen (BIIB - Free Report) , Gilead (GILD - Free Report) and Solid Biosciences (SLDB - Free Report) . All three carry a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Over the past 30 days, earnings estimates for Biogen have increased by 30 cents to $16.98. Biogen also surpassed estimates in three of the trailing four quarters, with the average being 7.02%.
Over the past 30 days, earnings estimates for Gilead have increased by 55 cents to $7.09. Gilead also surpassed estimates in three of the trailing four quarters, with the average being 0.35%.
Over the past 30 days, loss estimates for Solid Biosciences have narrowed to $8.04 from $10.15. SLDB missed estimates in three of the trailing four quarters, with the average being -4.15%.